08.01.19
CBD brand Elixinol has acquired the intellectual property rights over microencapsulated technology developed by Bionova. This transaction will allow Elixinol to utilize the technology globally. In addition, Bionova will be the exclusive manufacturer and supplier within the European Union of Elixinol products developed using the microencapsulated technology.
Bionova’s unique microencapsulation technology offers a wide variety of uses for food, beverage and nutraceutical product formulations. Other advantages of microencapsulation technology include:
Elixinol Global CEO Stratos Karousos, said: “Elixinol’s strategy is focused on developing new technologies, formulations and delivery systems to maximize bioavailability of our hemp-derived CBD products. We believe our CBD products will be enhanced by microencapsulation technology, providing multiple benefits to a diverse range of uses, particularly in the food, beverage and nutraceutical sectors.”
“By extending the useful life of cannabinoids and delivering them more efficiently in the human body, we can improve the health and well-being of many people,” said Bionova’s Jamie Fabregas Casal PhD, the inventor of the microencapsulation technology. “It is exciting to have Elixinol leverage the technology on a global scale.”
Consideration for the intellectual property rights are as follows:
Bionova’s unique microencapsulation technology offers a wide variety of uses for food, beverage and nutraceutical product formulations. Other advantages of microencapsulation technology include:
- Increased absorption into the human body;
- Increased efficacy of active ingredients within a product;
- Increased uniformity of ingredients within a product;
- Masking of unpleasant flavors or odors in finished products;
- Added protection against environmental factors inside the human body once ingested; and
- Better storage preservation of the encapsulated active ingredients.
Elixinol Global CEO Stratos Karousos, said: “Elixinol’s strategy is focused on developing new technologies, formulations and delivery systems to maximize bioavailability of our hemp-derived CBD products. We believe our CBD products will be enhanced by microencapsulation technology, providing multiple benefits to a diverse range of uses, particularly in the food, beverage and nutraceutical sectors.”
“By extending the useful life of cannabinoids and delivering them more efficiently in the human body, we can improve the health and well-being of many people,” said Bionova’s Jamie Fabregas Casal PhD, the inventor of the microencapsulation technology. “It is exciting to have Elixinol leverage the technology on a global scale.”
Consideration for the intellectual property rights are as follows:
- Bionova to be the exclusive manufacturer and supplier of Elixinol products developed by using the microencapsulated technology within the European Union based on minimum volumes of supply for the period established by law for any of the intellectual property rights related to the microencapsulation technology; and
- An annual fixed amount of €25,000 for each non-European Union country in which Elixinol exploits the microencapsulated technology until patent rights over the microencapsulated technology have been granted in that country, increasing to €50,000 annually once patent rights are granted.
